Cosmo Pharmaceuticals has announced positive Phase 3 clinical trial results for its topical clascoterone solution, a new potential treatment for male pattern baldness. The drug acts locally at hair follicles by blocking androgen receptors and reducing DHT signaling, aiming to promote hair regrowth without systemic hormonal side effects associated with oral treatments. The trials, SCALP 1 and SCALP 2, involved over 1,400 men and showed improved hair count and patient-reported outcomes with a favorable safety profile, potentially offering a novel approach to treating androgenetic alopecia.